Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Non-Current Deffered Revenue (2019 - 2020)

Vaxcyte (PCVX) has 2 years of Non-Current Deffered Revenue data on record, last reported at $10000.0 in Q4 2020.

  • On a quarterly basis, Non-Current Deffered Revenue fell 41.18% to $10000.0 in Q4 2020 year-over-year; TTM through Dec 2020 was $10000.0, a 41.18% decrease, with the full-year FY2020 number at $10000.0, down 41.18% from a year prior.
  • Non-Current Deffered Revenue reached $10000.0 in Q4 2020 per PCVX's latest filing, up from $1000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PCVX hit a ceiling of $17000.0 in Q4 2019 and a floor of $1000.0 in Q3 2020.